Top 100 Contractors in PSC 6505: Drugs and Biologicals, FY2021

Parent companies by net contract obligations Oct 1, 2020 – Sep 30, 2021 Code page on GovTribe

The top 10 won 96% of FY2021 PSC 6505 contract dollars

Ranking facts

Contract obligations
$54,731,983,817 Net of deobligations, by contracts coded PSC 6505
Contractors
553 Parent companies with an obligation
Largest contractor
Pfizer Inc. $23.1 billion, 41.8% of obligations
Data as of

Contract actions from FPDS (SAM.gov). How the rankings work · Download all 100 rows as CSV

Full ranking

Rank Contractor Net obligations Share Trend
1 $23,135,431,230
Rank history: #1 in FY2022, #4 in FY2023, not on the FY2024 list and #61 in FY2025; new, not ranked in FY2020.
2 $11,691,182,664
Rank history: #2 in FY2022, #1 in FY2023, #1 in FY2024 and #1 in FY2025; down 1 since FY2020.
3 $6,920,591,679
Rank history: #4 in FY2022 and not on the FY2023–FY2025 lists; unchanged since FY2020.
4 $5,565,148,165
Rank history: not on the FY2022–FY2025 lists; new, not ranked in FY2020.
5 $1,931,006,454
Rank history: #6 in FY2022, #3 in FY2023, #2 in FY2024 and #2 in FY2025; down 3 since FY2020.
6 $1,913,730,016
Rank history: #3 in FY2022 and not on the FY2023–FY2025 lists; new, not ranked in FY2020.
7
Merck & Co. Inc. 2 awardees, including Merck Sharp & Dohme LLC
$1,208,123,338
Rank history: #7 in FY2022, #14 in FY2023 and not on the FY2024–FY2025 lists; up 160 since FY2020.
8 $317,783,623
Rank history: #5 in FY2022, #45 in FY2023, #11 in FY2024 and #18 in FY2025; down 2 since FY2020.
9 $287,149,933
Rank history: not on the FY2022–FY2025 lists; up 347 since FY2020.
10 $231,561,221
Rank history: #10 in FY2022, #5 in FY2023, #5 in FY2024 and #3 in FY2025; down 3 since FY2020.
11 $194,895,927
Rank history: #75 in FY2022, #58 in FY2023 and not on the FY2024–FY2025 lists; up 65 since FY2020.
12 $126,000,000
Rank history: not on the FY2022–FY2025 lists; new, not ranked in FY2020.
13 $95,497,600
Rank history: #9 in FY2022, #8 in FY2023, #6 in FY2024 and #5 in FY2025; down 3 since FY2020.
14 $89,085,333
Rank history: #15 in FY2022, #23 in FY2023 and not on the FY2024–FY2025 lists; down 9 since FY2020.
15 $69,300,000
Rank history: not on the FY2022–FY2025 lists; new, not ranked in FY2020.
16 $69,176,881
Rank history: #16 in FY2022, #7 in FY2023 and not on the FY2024–FY2025 lists; down 5 since FY2020.
17 $63,612,248
Rank history: not on the FY2022–FY2025 lists; new, not ranked in FY2020.
18 $53,519,022
Rank history: #28 in FY2022, #27 in FY2023, #22 in FY2024 and not on the FY2025 list; up 7 since FY2020.
19 $49,996,340
Rank history: #26 in FY2022 and not on the FY2023–FY2025 lists; new, not ranked in FY2020.
20 $49,630,288
Rank history: #18 in FY2022, #9 in FY2023, #9 in FY2024 and #8 in FY2025; down 5 since FY2020.
21 $45,217,239
Rank history: #23 in FY2022, #10 in FY2023, #20 in FY2024 and #28 in FY2025; down 8 since FY2020.
22
Teva Pharmaceutical Industries Ltd. Through Teva Pharmaceuticals Usa, Inc.
$39,904,187
Rank history: #24 in FY2022, #12 in FY2023, #40 in FY2024 and not on the FY2025 list; down 1 since FY2020.
23 $39,418,684
Rank history: #40 in FY2022 and not on the FY2023–FY2025 lists; new, not ranked in FY2020.
24 $38,961,000
Rank history: not on the FY2022–FY2025 lists; down 10 since FY2020.
25 $34,953,404
Rank history: not on the FY2022–FY2023 lists, #21 in FY2024 and #36 in FY2025; new, not ranked in FY2020.
26 $31,618,151
Rank history: not on the FY2022 list, #11 in FY2023, #26 in FY2024 and #44 in FY2025; down 18 since FY2020.
27 $25,640,549
Rank history: #31 in FY2022, #69 in FY2023, not on the FY2024 list and #68 in FY2025; up 53 since FY2020.
28 $22,972,183
Rank history: #30 in FY2022, #19 in FY2023, #29 in FY2024 and not on the FY2025 list; down 6 since FY2020.
29 $22,501,800
Rank history: not on the FY2022–FY2024 lists and #19 in FY2025; up 6 since FY2020.
30 $21,000,000
Rank history: not on the FY2022–FY2025 lists; new, not ranked in FY2020.
31 $17,453,470
Rank history: #27 in FY2022, #13 in FY2023, #17 in FY2024 and #17 in FY2025; down 1 since FY2020.
32 $16,944,050
Rank history: #32 in FY2022, #24 in FY2023 and not on the FY2024–FY2025 lists; down 12 since FY2020.
33 $15,295,475
Rank history: not on the FY2022–FY2025 lists; up 122 since FY2020.
34 $14,611,967
Rank history: #37 in FY2022 and not on the FY2023–FY2025 lists; down 2 since FY2020.
35 $12,506,222
Rank history: not on the FY2022–FY2025 lists; down 2 since FY2020.
36 $11,000,000
Rank history: #34 in FY2022, #28 in FY2023 and not on the FY2024–FY2025 lists; down 18 since FY2020.
37 $9,990,164
Rank history: #51 in FY2022, #47 in FY2023, #53 in FY2024 and #72 in FY2025; up 55 since FY2020.
38 $8,845,848
Rank history: #46 in FY2022, #21 in FY2023, #39 in FY2024 and not on the FY2025 list; up 33 since FY2020.
39
Mylan Pharmaceuticals Inc. 2 awardees, including Mylan Specialty LP
$8,250,000
Rank history: not on the FY2022–FY2025 lists; up 178 since FY2020.
40
Dakco Distributors Inc. Through Dakota Drug, Inc.
$8,056,121
Rank history: #41 in FY2022, #30 in FY2023, #35 in FY2024 and not on the FY2025 list; up 1 since FY2020.
41 $7,902,695
Rank history: #33 in FY2022, #20 in FY2023, #28 in FY2024 and #22 in FY2025; down 4 since FY2020.
42 $7,860,287
Rank history: #47 in FY2022, #26 in FY2023, #41 in FY2024 and #46 in FY2025; down 15 since FY2020.
43 $6,932,000
Rank history: #43 in FY2022, not on the FY2023 list, #30 in FY2024 and #93 in FY2025; down 5 since FY2020.
44
Catalent Indiana LLC
$6,640,000
Rank history: not on the FY2022–FY2025 lists; up 34 since FY2020.
45 $6,551,557
Rank history: #48 in FY2022, #18 in FY2023, #24 in FY2024 and not on the FY2025 list; up 17 since FY2020.
46 $6,215,158
Rank history: #39 in FY2022, not on the FY2023 list, #62 in FY2024 and #67 in FY2025; up 123 since FY2020.
47 $5,920,615
Rank history: not on the FY2022–FY2025 lists; new, not ranked in FY2020.
48 $5,829,053
Rank history: #52 in FY2022, #51 in FY2023, #81 in FY2024 and #83 in FY2025; up 10 since FY2020.
49 $5,501,584
Rank history: #77 in FY2022, #57 in FY2023, not on the FY2024 list and #70 in FY2025; down 10 since FY2020.
50 $5,347,543
Rank history: #63 in FY2022, #42 in FY2023, #48 in FY2024 and not on the FY2025 list; down 10 since FY2020.
51 $5,243,442
Rank history: #71 in FY2022, #31 in FY2023, #49 in FY2024 and not on the FY2025 list; up 4 since FY2020.
52 $4,634,483
Rank history: #59 in FY2022, #96 in FY2023, #66 in FY2024 and not on the FY2025 list; up 32 since FY2020.
53 $4,500,000
Rank history: not on the FY2022–FY2025 lists; new, not ranked in FY2020.
54 $4,337,022
Rank history: #45 in FY2022, #15 in FY2023, #51 in FY2024 and not on the FY2025 list; down 38 since FY2020.
55 $4,235,690
Rank history: not on the FY2022–FY2025 lists; down 2 since FY2020.
56 $4,216,811
Rank history: #49 in FY2022, #38 in FY2023, #50 in FY2024 and #57 in FY2025; up 26 since FY2020.
57 $4,190,965
Rank history: #60 in FY2022, #50 in FY2023, #52 in FY2024 and #47 in FY2025; down 13 since FY2020.
58 $4,130,740
Rank history: #55 in FY2022, #40 in FY2023, #47 in FY2024 and #39 in FY2025; up 212 since FY2020.
59
Heyl Chemisch-Pharmazeutische Fabrik GMBH & Co. KG Through Heyltex Corporation
$3,381,566
Rank history: not on the FY2022–FY2025 lists; unchanged since FY2020.
60 $3,367,526
Rank history: #54 in FY2022 and not on the FY2023–FY2025 lists; new, not ranked in FY2020.
61 $3,162,500
Rank history: #99 in FY2022, #49 in FY2023, not on the FY2024 list and #54 in FY2025; down 18 since FY2020.
62 $3,025,955
Rank history: #86 in FY2022, #98 in FY2023, #64 in FY2024 and not on the FY2025 list; up 226 since FY2020.
63 $3,016,332
Rank history: not on the FY2022 list, #62 in FY2023 and not on the FY2024–FY2025 lists; up 355 since FY2020.
64
Fresenius Kabi LLC 2 awardees, including Fenwal, Inc.
$2,989,712
Rank history: #82 in FY2022, #22 in FY2023, #42 in FY2024 and not on the FY2025 list; down 47 since FY2020.
65 $2,968,536
Rank history: #66 in FY2022 and not on the FY2023–FY2025 lists; up 45 since FY2020.
66 $2,821,734
Rank history: #81 in FY2022, #59 in FY2023, #75 in FY2024 and #88 in FY2025; up 83 since FY2020.
67 $2,694,334
Rank history: #62 in FY2022 and not on the FY2023–FY2025 lists; up 12 since FY2020.
68 $2,549,569
Rank history: #74 in FY2022, #25 in FY2023 and not on the FY2024–FY2025 lists; down 49 since FY2020.
69 $2,524,698
Rank history: #57 in FY2022, #54 in FY2023 and not on the FY2024–FY2025 lists; up 1 since FY2020.
70 $2,400,193
Rank history: not on the FY2022–FY2025 lists; new, not ranked in FY2020.
71 $2,382,048
Rank history: #85 in FY2022, #39 in FY2023, #46 in FY2024 and #41 in FY2025; up 40 since FY2020.
72 $2,367,527
Rank history: #70 in FY2022, #61 in FY2023, #84 in FY2024 and #71 in FY2025; up 33 since FY2020.
73 $2,351,012
Rank history: #95 in FY2022, #71 in FY2023, #91 in FY2024 and #45 in FY2025; down 9 since FY2020.
74 $2,339,657
Rank history: not on the FY2022 list, #60 in FY2023, #89 in FY2024 and not on the FY2025 list; up 25 since FY2020.
75 $2,204,214
Rank history: not on the FY2022–FY2025 lists; up 312 since FY2020.
76 $2,057,054
Rank history: #64 in FY2022, #46 in FY2023, #54 in FY2024 and #59 in FY2025; down 4 since FY2020.
77 $1,886,155
Rank history: not on the FY2022 list, #94 in FY2023 and not on the FY2024–FY2025 lists; up 8 since FY2020.
78
Avista Pharma Solutions Inc.
$1,837,747
Rank history: not on the FY2022–FY2025 lists; new, not ranked in FY2020.
79 $1,801,677
Rank history: not on the FY2022 list, #66 in FY2023, #73 in FY2024 and not on the FY2025 list; up 263 since FY2020.
80 $1,759,020
Rank history: #80 in FY2022, #55 in FY2023, #71 in FY2024 and #84 in FY2025; up 166 since FY2020.
81 $1,721,425
Rank history: #87 in FY2022 and not on the FY2023–FY2025 lists; up 48 since FY2020.
82 $1,584,974
Rank history: #89 in FY2022, #78 in FY2023, #96 in FY2024 and not on the FY2025 list; up 15 since FY2020.
83
Miltenyi Biotec, Inc.
$1,493,784
Rank history: #94 in FY2022 and not on the FY2023–FY2025 lists; up 65 since FY2020.
84 $1,427,178
Rank history: #68 in FY2022, #52 in FY2023, #58 in FY2024 and not on the FY2025 list; new, not ranked in FY2020.
85 $1,389,715
Rank history: not on the FY2022–FY2025 lists; new, not ranked in FY2020.
86 $1,372,634
Rank history: #65 in FY2022, #44 in FY2023, #83 in FY2024 and #56 in FY2025; up 40 since FY2020.
87 $1,362,530
Rank history: not on the FY2022–FY2025 lists; down 40 since FY2020.
88 $1,334,790
Rank history: #84 in FY2022, #72 in FY2023, not on the FY2024 list and #76 in FY2025; down 1 since FY2020.
89 $1,255,904
Rank history: not on the FY2022–FY2025 lists; up 136 since FY2020.
90 $1,209,463
Rank history: not on the FY2022 list, #85 in FY2023 and not on the FY2024–FY2025 lists; new, not ranked in FY2020.
91
Cambridge Isotope Laboratories Inc. 2 awardees, including Otsuka America Pharmaceutical Inc.
$1,195,823
Rank history: #69 in FY2022, #87 in FY2023 and not on the FY2024–FY2025 lists; up 50 since FY2020.
92 $1,164,685
Rank history: not on the FY2022–FY2025 lists; up 69 since FY2020.
93 $1,151,828
Rank history: not on the FY2022–FY2025 lists; up 192 since FY2020.
94 $1,150,461
Rank history: #42 in FY2022, #29 in FY2023, #36 in FY2024 and not on the FY2025 list; up 64 since FY2020.
95 $1,138,200
Rank history: not on the FY2022–FY2025 lists; down 27 since FY2020.
96 $1,102,908
Rank history: not on the FY2022–FY2023 lists, #94 in FY2024 and #94 in FY2025; up 38 since FY2020.
97 $1,093,131
Rank history: #90 in FY2022, #77 in FY2023, #67 in FY2024 and not on the FY2025 list; up 3 since FY2020.
98 $1,091,944
Rank history: #93 in FY2022, #63 in FY2023, #70 in FY2024 and not on the FY2025 list; down 2 since FY2020.
99 $1,060,984
Rank history: not on the FY2022–FY2025 lists; up 163 since FY2020.
100 $1,000,000
Rank history: not on the FY2022–FY2025 lists; down 40 since FY2020.
Show 75 more

100 of 553 contractors listed here. See the rest on GovTribe.

How this ranking works

  • Source: every contract action FPDS records (as published on SAM.gov) in the period, as GovTribe received it.
  • Amounts are net obligations: what was obligated, less what was deobligated. Shares are of $55.3 billion obligated before deobligations, so they never pass 100%.
  • Parent companies: each action counts under the ultimate parent its award record names, or under the awardee when it names none, so no dollar counts twice. Parents of the same name (Inc., LLC and the like aside) count as one company, since FPDS records a company's parent under more than one UEI over time. GovTribe corrects a few parents and names by hand; see the corrections.
  • Fiscal year 2021 ran Oct 1, 2020 – Sep 30, 2021. The Department of Defense reports its contract actions to FPDS about 90 days late, so a fiscal year is ranked once they're in, in February, and the list doesn't change after.
  • Rank changes compare with FY2020. "New" marks a company outside that period's top 500, and "Returned" one of those that was on an earlier fiscal year's list.
  • Rank lines show each company's rank on every fiscal year's list since FY2021, #1 at the top, on a scale that gives the top of the list more room. A dashed stretch spans years it wasn't on the list. The step from FY2020 takes the color of the rank change beside it.
  • Placeholder recipients FPDS uses when it names no company ("Miscellaneous Foreign Contractors" and the like) aren't ranked.

Quick answers

Who were the top 10 PSC 6505 contractors in FY2021?

1. Pfizer Inc. ($23.1B), 2. Mckesson Corporation ($11.7B), 3. Modernatx Inc. ($6.92B), 4. Regeneron Pharmaceuticals Inc. ($5.57B), 5. Cencora, Inc. ($1.93B), 6. ELI Lilly and Company ($1.91B), 7. Merck & Co. Inc. ($1.21B), 8. Glaxosmithkline LLC ($318M), 9. Astrazeneca PLC ($287M), 10. DMS Pharmaceutical Group Inc. ($232M).

On GovTribe

Research every contractor on this list

  • Every contract, task order and IDV they hold
  • Their subsidiaries, teammates and competitors
  • Open opportunities they're positioned for
  • Alerts when they win new work